Anetumab ravtansine was evaluated in a phase II multicenter study involving mesothelin positive (defined as 2+ or 3+ mesothelin membrane staining in at least 30% of viable tumor cells) patients with PM previously treated with platinum-based therapy [90]. Here, MSLN is linked to neoplasm.